Peter Nightingale - Biotron Insider

BITRF -- USA Stock  

USD 0.0167  0.0007  4.38%

  Executive
Mr. Peter James Nightingale was Company Secretary of Biotron Ltd since February 23, 1999. Mr. Nightingale graduated with a Bachelor of Economics degree from the University of Sydney and is a member of the Institute of Chartered Accountants in Australia. He has worked as achartered accountant in both Australia and the USA. As a director or company secretary Mr. Nightingale has, for more than 25 years, been responsible for the financial control, administration, secretarial and inhouse legal functions of a number of private and public listed companies in Australia, the USA and Europe including Bolnisi Gold N.L., Callabonna Uranium Limited, Mogul Mining N.L., Pangea Resources Limited, Perseverance Corporationrationration Limited, Sumatra Copper Gold plc, Timberline Minerals, Inc. and Valdora Minerals N.L. Mr. Nightingale is currently a director of ASX listed Augur Resources Ltd, Cockatoo Coal Limited and Planet Gas Limited and unlisted public companies Equus Resources Limited and Nickel Mines Limited.
  Executive Since 1999      
61 2 9805 0488  http://www.biotron.com.au

Management Efficiency

The company has return on total asset (ROA) of (54.71) % which means that it has lost $54.71 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (117.11) % meaning that it generated substantial loss on money invested by shareholders.

Similar Executives

Showing few of many executives

EXECUTIVE Since

Raimon RouraGrifols S A
2017
Darin LippoldtNeurocrine Biosciences
2016
Julie CookeNeurocrine Biosciences
2017
Karen SmithJazz Pharmaceuticals Public Lim
2015
Eva TubauGrifols S A
2014
Annette SuchAmgen
2015
Nuria BarnesGrifols S A
2015
Mark DehringCSL Limited
2014
John LevyCSL Limited
2017
Christopher OBrienNeurocrine Biosciences
2007
Navjot RaiNeurocrine Biosciences
Eric BenevichNeurocrine Biosciences
2015
Haig BozigianNeurocrine Biosciences
2012
Arvind SoodAmgen
2012
Fiona MeadCSL Limited
2018
Eiry RobertsNeurocrine Biosciences
2018
Bernard RonchiCSL Limited
2015
Montserrat CalvoGrifols S A
2017
Jane SorensenNeurocrine Biosciences
N/A
Edward BaileyCSL Limited
2017
Dimitri GrigoriadisNeurocrine Biosciences
2007

Entity Summary

Biotron Limited, a biotechnology company, develops and commercializes novel small molecule antiviral therapeutics to treat various viral diseases in Australia. The company also has a portfolio of preclinical antiviral programs developing drugs targeting a range of viruses, including dengue, ebola, influenza, and zika, as well as Middle East respiratory virus. Biotron operates under Biotechnology classification in USA and traded on OTC Market. It employs 3 people.Biotron Limited (BITRF) is traded on OTC Market in USA. It is located in 56 Delhi Road and employs 3 people.

Biotron Limited Leadership Team

Robert Thomas, Independent Non-Executive Director
Peter Nightingale, Company Secretary
Michael Hoy, Independent Non-Executive Chairman of the Board
Michelle Miller, CEO, Managing Director, Executive Director
Denis Wade, Independent Non-Executive Director
Susan Pond, Independent Non-Executive Director

Stock Performance Indicators

Current Sentiment - BITRF

Biotron Limited Investor Sentiment

Macroaxis portfolio users are unresponsive in their opinion about investing in Biotron Limited. What is your opinion about investing in Biotron Limited? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Biotron Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Biotron and Amgen. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try ETF Directory module to find actively-traded exchange traded funds (etf) from around the world.
Search macroaxis.com